RecruitingPhase 2

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

United States25 participantsStarted 2025-12-03

Plain-language summary

This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * History of uncontrolled gout * Presence of ≥1 clinically visible tophus * Last uricase infusion occurred ≥3 months * Body weight no less than 50 kg * Serum creatinine must be \< 3.0 mg/dL and estimated CLcr ≥ 40 mL/min Exclusion Criteria: * Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin * Pregnant or breastfeeding * History of symptomatic kidney stones within the past 6 months * Received pegloticase, rasburicase or other experimental uricases within the last 3 months

What they're measuring

Serum urate (uric acid) (sUA) level < 6 mg/dL at month 6

Timeframe: 24 weeks

Trial details

NCT IDNCT07116746

SponsorArthrosi Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-07

Contact for this trial

Director Clinical Operations

+1 858-437-9123 AR882-204@Arthrosi.com

View on ClinicalTrials.gov More Gout trials